Minerva Neurosciences to Participate in Two Upcoming Investor ConferencesGlobeNewsWire · Aug 28, 2026
Analysts Set Minerva Neurosciences, Inc (NASDAQ:NERV) Target Price at $10.50Defense World · Aug 17, 2026
Minerva Neurosciences Provides Second Quarter 2026 Financial Results and Business UpdatesGlobeNewsWire · Aug 7, 2026Minerva Neurosciences, Inc. functions as a biopharmaceutical firm in the clinical development stage, primarily dedicated to uncovering and bringing to market novel therapeutic options for disorders affecting the central nervous system. Its portfolio of experimental treatments notably features roluperidone, an investigational drug aimed at managing schizophrenia, alongside MIN-301, a soluble recombinant variant of the neuregulin-1b1 protein, which is being explored for its potential in treating Parkinson's disease and various other neurodegenerative conditions. The company has a contractual licensing agreement with Mitsubishi Tanabe Pharma Corporation, authorizing the worldwide development, distribution, and import of roluperidone, with the explicit exclusion of the Asian continent.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 7, 2026 | -$0.19 | -$0.14 | Beat |
| May 5, 2026 | -$0.13 | -$2.86 | Miss |
| Mar 11, 2026 | -$0.11 | -$0.64 | Miss |
| Nov 5, 2025 | -$0.35 | -$0.36 | Miss |
| Aug 14, 2025 | -$0.95 | -$0.43 | Beat |
| May 13, 2025 | -$1.07 | -$0.50 | Beat |